StockData
Insulet Corp logo

Insulet Corp (PODD) stock

PODDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 20/3039% below fair value
$149.68−2.82 (-1.85%)

Close on Oct 30, 2026Market cap $10.38BP/E 28.0Yield –

Earnings

Insulet's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 5, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q2 FY2026
$801.70M
+23.5% on a year earlier
Adjusted diluted earnings per share, Q2 FY2026
$1.66
$1.17 a year earlier
Latest guidance
Raised
Aug 5, 2026 · 22 items

Quarterly results

Revenue and earnings per share from each of Insulet's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q3 FY2026ended Sep 30, 2026Nov 5, 2026Expected–––––
Q2 FY2026ended Jun 30, 2026Aug 5, 2026before the open$801.70M+23.5%$1.37$1.66Release
Q1 FY2026ended Mar 31, 2026May 6, 2026before the open$761.70M+33.9%$1.30$1.42Release
Q4 FY2025ended Dec 31, 2025Feb 18, 2026before the open$783.80M+31.2%$1.44$1.55Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025before the open$706.30M+29.9%$1.24$1.24Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025before the open$649.10M+32.9%$0.32$1.17Release
Q1 FY2025ended Mar 31, 2025May 8, 2025after the close$569.00M+28.8%$0.50$1.02Release
Q4 FY2024ended Dec 31, 2024Feb 20, 2025after the close$597.50M+17.2%$1.39$1.15Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024after the close$543.90M+25.7%$1.08$0.90Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024after the close$488.50M+23.2%$2.59$0.55Release
Q1 FY2024ended Mar 31, 2024May 9, 2024after the close$441.70M+23.3%$0.73–Release
Q4 FY2023ended Dec 31, 2023Feb 22, 2024after the close$509.80M+37.9%$1.44$1.40Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Insulet's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
U.S. OmnipodGAAPQ3 FY2026+14% – +16%–NewAug 5, 2026
U.S. Omnipodnon-GAAPQ3 FY2026+14% – +16%–NewAug 5, 2026
Adjusted Operating Marginnon-GAAPQ3 FY2026100–NewAug 5, 2026
Total OmnipodGAAPFY2026+22% – +24%+20% – +22%LoweredAug 5, 2026
U.S. Omnipodnon-GAAPFY2026+17% – +19%+20% – +22%LoweredAug 5, 2026
Adjusted Operating Marginnon-GAAPFY2026100–NewAug 5, 2026
Adjusted EPS Growthnon-GAAPFY2026+30%+25%RaisedAug 5, 2026

Guidance vs results

The last range Insulet gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
Q2 FY2026Revenue growth+18% – +20%+23.51%Above range
Q1 FY2026Revenue growth+24% – +26%+33.87%Above range
FY2025Revenue growth+26% – +27%+30.73%Σ4QAbove range
Q4 FY2025Revenue growth+24% – +27%+31.18%Above range
Q3 FY2025Revenue growth+21% – +24%+29.86%Above range
Q2 FY2025Revenue growth+22% – +25%+32.88%Above range
Q1 FY2025Revenue growth+21% – +24%+28.82%Above range
Q4 FY2024Revenue growth+12% – +15%+17.2%Above range
Q3 FY2024Revenue growth+18% – +21%+25.7%Above range
Q2 FY2024Revenue growth+15% – +18%+23.2%Above range
Q1 FY2024Revenue growth+17% – +20%+23.35%Above range
Q4 FY2023Revenue growth+22% – +25%+37.9%Above range

Guidance history

Every forecast Insulet put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 5, 2026Adjusted EPS GrowthFY2026+30%Raised
Aug 5, 2026Adjusted Operating MarginFY2026100New
Aug 5, 2026Adjusted Operating MarginQ3 FY2026100New
Aug 5, 2026Total OmnipodFY2026+22% – +24%Lowered
Aug 5, 2026Drug DeliveryFY2026-40%Lowered
Aug 5, 2026U.S. OmnipodFY2026+17% – +19%Lowered
Aug 5, 2026International OmnipodFY2026+30% – +32%Raised
Aug 5, 2026TotalFY2026+21% – +23%Raised
Aug 5, 2026TotalFY2026+20% – +22%Lowered
Aug 5, 2026U.S. OmnipodQ3 FY2026+14% – +16%New
Aug 5, 2026International OmnipodQ3 FY2026+26% – +28%Raised
Aug 5, 2026Total OmnipodQ3 FY2026+17.5% – +19.5%Lowered
Aug 5, 2026Drug DeliveryQ3 FY2026-20%Lowered
Aug 5, 2026TotalQ3 FY2026+17% – +19%Raised
Aug 5, 2026U.S. OmnipodQ3 FY2026+14% – +16%New
Aug 5, 2026International OmnipodQ3 FY2026+28% – +30%Raised
Aug 5, 2026Total OmnipodQ3 FY2026+18% – +20%Lowered
Aug 5, 2026Drug DeliveryQ3 FY2026-20%Lowered
Aug 5, 2026TotalQ3 FY2026+17.5% – +19.5%Raised
Aug 5, 2026Total OmnipodFY2026+21% – +23%Lowered

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Insulet filed with the SEC as exhibits to Form 8-K or 6-K

  1. Insulet Reports Second Quarter 2026 Results
    Results
  2. Insulet Announces Appointment of Jonathan J. Mazelsky to its Board of Directors
    Update
  3. Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® Pods in the U.S. and Affected International Markets
    Update
  4. Insulet Reports First Quarter 2026 Results
    Results
  5. Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® 5 Pods in the U.S.
    Update
  6. Insulet Reports Fourth Quarter and Full Year 2025 Results
    Results
  7. Insulet Reports Third Quarter 2025 Results
    Results
  8. Insulet Announces Appointment of Robert L. Huffines to its Board of Directors
    Update
  9. Flavia Pease Appointed Chief Financial Officer
    News
  10. Insulet Reports Second Quarter 2025 Revenue Increase of 32.9%
    Results
  11. Insulet Reports First Quarter 2025 Revenue Increase of 29%
    Results
  12. Insulet Appoints Ashley McEvoy President and CEO
    Update
  13. Insulet Announces Pricing of Senior Notes Due 2033
    Update
  14. Insulet Announces Proposed Financing Transactions
    Update
  15. Insulet Reports Full Year 2024 Revenue Increase of 22%
    Results